Answer
Agalsidase alfa breaks down globotriaosylceramide (Gb3) in Fabry disease by catalysing its hydrolysis, cleaving a terminal galactose residue from the molecule.
Sources for this answer
- Replagal 1mg/ml concentrate for solution for infusionTakeda UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 20Document updated
Sources checked